Burnett Mary Susan, Devaney Joseph M, Adenika Remi J, Lindsay Robert, Howard Barbara V
Cardiovascular Research Institute, MedStar Research Institute, Washington, DC 20010, USA.
J Clin Endocrinol Metab. 2006 Jan;91(1):64-8. doi: 10.1210/jc.2005-1653. Epub 2005 Oct 25.
Recently, resistin was found to be present in atherosclerotic lesions in apoE(-/-) mice. Resistin may be associated with inflammation and atherosclerosis in humans; however, the role of resistin in human disease remains controversial.
This study assesses cross-sectional relationships of resistin with coronary heart disease (CHD).
DESIGN, SETTING, AND PARTICIPANTS: Blood samples from the third examination of the Strong Heart Study (SHS)--the largest study of CHD in American Indians--were used. Cases who had suffered previous myocardial infarction (n = 100) were selected randomly from the three SHS sites and matched for study site and sex with controls who had no history of cardiovascular disease (CHD or stroke) (n = 100).
Resistin levels by enzyme-linked immunosorbent assay method in cases and controls was the main outcome measure.
Resistin levels were higher in cases than controls [median (interquartile range): 3.4 (2.5-4.7) vs. 2.8 (2.1-4.0) ng/ml; P = 0.003] and had univariate correlations with age (Spearman r = 0.21; P < 0.002), fasting insulin (r = 0.21; P = 0.003), insulin resistance by homeostasis model (r = 0.22; P = 0.04), albumin to creatinine ratio (r = 0.19; P = 0.01), and fibrinogen (r = 0.34; P < 0.0001). Cases were more likely to have diabetes (cases 67%; controls 41%; P < 0.0001) but had similar body mass index (cases 31.4 +/- 5.4; controls 30.7 +/- 6.3; P = 0.85). Resistin levels were higher in participants with established nephropathy (albumin to creatinine ratio >300 mg/g, n = 26) compared with those with normo- (n = 122) or microalbuminuria (n = 42). In multivariate analysis, nephropathy (P = 0.0013) but not previous myocardial infarction (P = 0.12) was significantly associated with resistin.
Resistin is not independently associated with CHD. Resistin is elevated in survivors of myocardial infarction; however, this reflects a novel association of raised resistin with diabetic nephropathy.
最近,研究发现抵抗素存在于载脂蛋白E基因敲除(apoE(-/-))小鼠的动脉粥样硬化病变中。抵抗素可能与人类的炎症和动脉粥样硬化有关;然而,抵抗素在人类疾病中的作用仍存在争议。
本研究评估抵抗素与冠心病(CHD)的横断面关系。
设计、地点和参与者:使用了来自强心脏研究(SHS)第三次检查的血样,SHS是美国印第安人中关于冠心病的最大规模研究。曾患心肌梗死的病例(n = 100)从SHS的三个研究地点中随机选取,并在研究地点和性别上与无心血管疾病(冠心病或中风)病史的对照组(n = 100)进行匹配。
采用酶联免疫吸附测定法测定病例组和对照组的抵抗素水平作为主要观察指标。
病例组的抵抗素水平高于对照组[中位数(四分位间距):3.4(2.5 - 4.7)对2.8(2.1 - 4.0)ng/ml;P = 0.003],并且与年龄(Spearman相关系数r = 0.21;P < 0.002)、空腹胰岛素(r = 0.21;P = 0.003)、稳态模型评估的胰岛素抵抗(r = 0.22;P = 0.04)、白蛋白与肌酐比值(r = 0.19;P = 0.01)以及纤维蛋白原(r = 0.34;P < 0.0001)存在单变量相关性。病例组患糖尿病的可能性更高(病例组67%;对照组41%;P < 0.0001),但两组的体重指数相似(病例组31.4 ± 5.4;对照组30.7 ± 6.3;P = 0.85)。与肾功能正常(n = 122)或微量白蛋白尿(n = 42)的参与者相比,已确诊肾病(白蛋白与肌酐比值>300 mg/g,n = 26)的参与者抵抗素水平更高。在多变量分析中,肾病(P = 0.0013)而非既往心肌梗死(P = 0.12)与抵抗素显著相关。
抵抗素与冠心病无独立相关性。心肌梗死幸存者的抵抗素水平升高;然而,这反映了抵抗素升高与糖尿病肾病之间的一种新关联。